Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease
about
Anti-IL-12/23p40 antibodies for induction of remission in Crohn's diseaseUstekinumab in treatment of Crohn's disease: design, development, and potential place in therapyBiomarkers as potential treatment targets in inflammatory bowel disease: A systematic reviewSecukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.Review of the safety and efficacy of ustekinumabCurrent and emerging drugs for the treatment of inflammatory bowel disease.Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.Joint involvement in inflammatory bowel disease: managing inflammation outside the digestive system.The use of ustekinumab in autoimmune disease.Cytokine blockade in inflammatory bowel diseases.The IL-23/IL-17 pathway in inflammatory bowel disease.C-reactive protein in Crohn's disease: how informative is it?Role of biomarkers in the study and management of inflammatory bowel disease: a "nonsystematic" review.Pathway-based approaches to the treatment of inflammatory bowel disease.Biological therapy targeting the IL-23/IL-17 axis in inflammatory bowel disease.Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect?A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors.Emerging dermatological and systemic applications of ustekinumab: beyond its clinical use in psoriasisBiomarkers in inflammatory bowel diseases: insight into diagnosis, prognosis and treatment.Next generation of biologics for the treatment of Crohn's disease: an evidence-based review on ustekinumab.Serum C-reactive protein levels in Japanese patients with psoriasis and psoriatic arthritis: Long-term differential effects of biologics.Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort.Report of successful use of ustekinumab in Crohn's disease refractory to three anti-TNF therapies.Bacterial modulation of Tregs/Th17 in intestinal disease: a balancing act?
P2860
Q24188040-94E9C1DF-5FB8-4197-98A5-46BFC64C3158Q28067631-5E5E854F-7F2D-4232-BD9A-013915A3148CQ28087434-751B66FD-4445-4CC1-8F6B-8860E34D39A5Q34275637-51297993-D1D3-4597-B09C-D44231ECC5C5Q34625984-5495F056-3454-4E85-B656-A8ABDD377418Q34883210-08B32A32-00FF-4B95-A45E-FA5EB8885BCEQ36203845-1DBBBA7A-98B9-463E-8D62-184EC524F66DQ37688137-E5C56DE6-4549-4544-95AA-20BFFD55C8D0Q37706606-9A61B4FF-96F9-4C67-B44E-9A8CF7D30724Q37952792-1994748D-8C4C-426A-8906-BA54149F5D1BQ37989164-39AF8B29-86BF-4E17-A08C-B85E19A46B00Q38196441-02271A54-658D-4E05-A743-6BFA5289BED2Q38249415-2BF768AB-3D87-4EC1-B51D-AA985E4B010AQ38593257-1353DC89-ECD1-451E-8F99-1D0E4AEAB638Q38798137-79E6BC2E-83F2-486A-B6E2-9BB93B82BAAEQ38836998-4E03E1A6-1E85-4B8F-86E0-508C6739C267Q41995656-203C31DB-BEA7-409C-9197-B3F585CD2D2AQ42230941-ED6F4789-82F7-4C3C-B39D-A8D0FD44BD9BQ45898977-511AC8C8-8403-4AFC-8B91-EB54CDBDA776Q47141159-96FA850B-2EF8-4DEC-97F6-ED4A538A94A1Q47930789-1E3D00ED-7C4D-4AD6-BCB2-A85100160E6AQ50237402-FED38B61-950B-46B8-8179-4B52B0BDDDBFQ53291078-B5048FA0-A303-4448-B54B-1FC95578C87DQ53915109-1B416A34-35A9-40BC-B54B-80DE2B48205B
P2860
Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease
description
article
@en
im November 2009 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в листопаді 2009
@uk
name
Relationship of C-reactive pro ...... ustekinumab in Crohn's disease
@en
Relationship of C-reactive pro ...... ustekinumab in Crohn's disease
@nl
type
label
Relationship of C-reactive pro ...... ustekinumab in Crohn's disease
@en
Relationship of C-reactive pro ...... ustekinumab in Crohn's disease
@nl
prefLabel
Relationship of C-reactive pro ...... ustekinumab in Crohn's disease
@en
Relationship of C-reactive pro ...... ustekinumab in Crohn's disease
@nl
P2093
P356
P1476
Relationship of C-reactive pro ...... ustekinumab in Crohn's disease
@en
P2093
Gary P Toedter
Marion Blank
Willem J S de Villiers
Yinghua Lang
P2860
P304
P356
10.1038/AJG.2009.454
P407
P577
2009-11-01T00:00:00Z